Partner and Localizer of BRCA2 (PALB2) is a critical molecular scaffold bridging BRCA1 and BRCA2 in the homologous recombination (HR) DNA double-strand break repair pathway. As a key driver of synthetic lethality, PALB2 is a premier target for oncology drug discovery, particularly in breast, ovarian, and pancreatic cancers.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PALB2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PALB2 Recombinant Protein (WD40 Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PALB2 Products |
| Gene Delivery | PALB2 Promise-ORF / Lentivirus Full-length ORF and clinical mutant constructs for stable cell line generation. |
View PALB2 Products |
| Benchmark Ab | Anti-PALB2 Recombinant Antibody Sequence-verified positive control for Western Blot, IP, and IHC. |
View PALB2 Products |
| Validator | PALB2 siRNA Set For target knockdown and homologous recombination assay validation. |
View PALB2 Products |
| Related Target A | BRCA2 Direct binding partner of PALB2; key component of the HR repair complex. |
View BRCA2 Products |
| Related Target B | BRCA1 Binds the N-terminus of PALB2; essential for recruiting PALB2 to DNA double-strand breaks. |
View BRCA1 Products |
| Related Target C | PARP1 Primary target for synthetic lethality screening in PALB2-deficient tumors. |
View PARP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening (PALB2-BRCA2) | Truncated WD40 domain proteins available with >95% purity and verified molecular weight. |
| Resistance mutation profiling (e.g., secondary reversion mutations) | Custom mutant recombinant proteins and Lentivirus panels engineered with high-fidelity sequence verification. |
| Lack of Controls | Clinical benchmark antibodies and sequence-verified positive controls included. |
| False Positives in Knockdown | Validated multi-sequence siRNA pool included for specific gene knockdown verification. |
Live PALB2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PALB2 therapeutics is intensifying, with major players shifting focus from traditional PARP inhibitors to small molecule inhibitors targeting the PALB2-BRCA2 protein-protein interaction (PPI). As first-generation synthetic lethality therapies face resistance in the clinic, the next wave of R&D is targeting the disruption of the HR complex directly or utilizing PROTACs to selectively degrade PALB2 in homologous recombination-proficient tumors to sensitize them to DNA damaging agents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | FoRx Therapeutics, Academic Consortia | Breast Cancer, Pancreatic Cancer, Ovarian Cancer | High-throughput screening of WD40 domain binding (Need high-purity recombinant WD40 domain) |
| PROTAC / Degrader | Biotech Startups | Solid Tumors (HR-proficient) | Degradation kinetics and Western Blot validation (Need sequence-verified PALB2 antibodies) |
| Gene Therapy / Rescue | Translational Research Labs | PALB2-deficient hereditary cancers | Stable expression of functional PALB2 (Need Lentivirus Premade Particles) |